Fibrinogen-Like 2 (FGL2) ELISA Kits

The protein encoded by FGL2 is a secreted protein that is similar to the beta- and gamma-chains of fibrinogen. Additionally we are shipping Fibrinogen-Like 2 Antibodies (97) and Fibrinogen-Like 2 Proteins (14) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
FGL2 10875 Q14314
FGL2 84586  
FGL2 14190 P12804
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top Fibrinogen-Like 2 ELISA Kits at

Showing 10 out of 28 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Delivery Price Details
Mouse 0.135 ng/mL 0.31 ng/mL - 20 ng/mL 96 Tests 13 to 16 Days
Human 0.19 ng/mL 0.47 ng/mL - 30 ng/mL 96 Tests 13 to 16 Days
Rat 34 pg/mL 78.12 pg/mL - 5000 pg/mL 96 Tests 13 to 16 Days
Rabbit 1.0 pg/mL 250-5000 pg/mL   96 Tests 15 to 18 Days
Guinea Pig 1.0 pg/mL 250-5000 pg/mL   96 Tests 15 to 18 Days
Chicken 1.406 pg/mL 2.344-150 pg/mL   96 Tests 12 to 14 Days
Pig 28.125 pg/mL 46.875-3000 pg/mL   96 Tests 12 to 14 Days
Monkey 1.0 pg/mL 225-500 pg/mL   96 Tests 15 to 18 Days
Dog 1.0 pg/mL 250-5000 pg/mL   96 Tests 15 to 18 Days
  96 Tests 15 to 18 Days

Top referenced Fibrinogen-Like 2 ELISA Kits

  1. Mouse (Murine) FGL2 ELISA Kit for Sandwich ELISA - ABIN415690 : Chen, Wu, Guo, Fei, Guo, Yang, Fu, Wu: Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. in PLoS pathogens 2011 (PubMed)
    Show all 5 Pubmed References

  2. Human FGL2 ELISA Kit for Sandwich ELISA - ABIN414678 : Colak, Senates, Ozturk, Yilmaz, Coskunpinar, Kahraman, Sahin, Zemheri, Enc, Ulasoglu, Kiziltas, Kurdas, Tuncer: Plasma fibrinogen-like protein 2 levels in patients with non-alcoholic fatty liver disease. in Hepato-gastroenterology 2012 (PubMed)

More ELISA Kits for Fibrinogen-Like 2 Interaction Partners

Human Fibrinogen-Like 2 (FGL2) interaction partners

  1. Elevation of serum sFGL2 concentrations is strongly associated with the acute pancreatitis severity and has the potential to distinguish delirium after acute pancreatitis.

  2. The increase in intrahepatic and plasma sFGL2 by Tregs may restrict AIH progression by inhibiting conventional CD8+ T cells and Tc17 cell function. The high correlation between sFGL2 and disease severity may predict AIH outcome.

  3. The presence of infectious/autoimmune diseases does not significantly alter FGL2 activity in the peripheral blood

  4. FGL2 expression is a novel, independent, and an adverse prognostic factor of clinical outcomes in patients with clear cell renal cell carcinoma.

  5. Serum FGL2 is a promising biomarker for assessing the severity and prognosis in severe TBI

  6. FGL2 promotes tumor progression in the brain by suppressing CD103-expressing dendritic cell differentiation.

  7. serum levels of soluble FAS ligand (sFASL) and interferon gamma (IFN-gamma) were analyzed and correlated with sFGL2 levels in Hepatitis C Virus-Infected Patients and Hepatocellular Carcinoma Patients.

  8. Data suggest that fibrinogen-like protein 2 (hFGL2) gene silencing via miRNA may be an alternative strategy for the management of hepatocellular carcinoma (HCC).

  9. Our results identified FGL2, GAL, SEMA4D, SEMA7A, and IDO1 as new candidate genes that could be involved in MSCs-mediated immunomodulation. FGL2, GAL, SEMA4D, SEMA7A, and IDO1 genes appeared to be differentially transcribed in the different MSC populations. Moreover, these genes were not similarly modulated following MSCs-exposure to inflammatory signals

  10. Report increased expression of FGL-2 in peripheral blood mononuclear cells from mycosis fungoides patients.

  11. these results suggest that FGL-2 mediates angiogenesis and tumorigenesis not by thrombin-mediated mechanism but rather through FGF-2/ERK signaling pathway.

  12. Results show that FGL2 functions as a key immune-suppressive modulator and has potential as an immunotherapeutic target for treating glioblastoma multiforme (GBM).

  13. FGL-2 prothrombinase activity in PBMC of lymphoma patients is increased in active disease and normalizes during remission, thus being a potential marker for follow up of lymphoma patients.

  14. Studied fibrinogen-like protein 2 expression and its role in CRC metastasis and underlying molecular mechanisms; results suggest that FGL2 plays an important oncogenic role in CRC aggressiveness by inducing EMT.

  15. The selected peptide sequence NPG-12 may be a critical domain for hfgl2 prothrombinase activity.

  16. The proliferation index of CD8(+)T cells after blocking FGL2 was higher.

  17. immunomodulatory activity of FGL2 may be involved in the immunopathogenesis of inflammatory bowel disease

  18. Circulating fibrinogen-like protein 2 is increased in patients with systemic sclerosis.

  19. Serum fgl2 levels were increased among renal allograft recipients with acute rejection episodes to an extent dependent upon the pathological type and severity of the response.

  20. FGL2 contributes to hepatocellular carcinoma tumour growth and angiogenesis in a thrombin-dependent manner, and downregulation of its expression might be of therapeutic significance in HCC.

Pig (Porcine) Fibrinogen-Like 2 (FGL2) interaction partners

  1. soluble FGL2 might be a potential renoprotective mediator involved in the renal self-repairing and remodeling.

  2. studies of pig-to-baboon kidney xenografts undergoing acute vascular rejection in vivo revealed induction of pfgl2 expression on graft vascular endothelial cells.

Mouse (Murine) Fibrinogen-Like 2 (FGL2) interaction partners

  1. In the mouse fulminant hepatitis (FH) model revealed that CC10 protects against MHV-3-induced FH via suppression of Fgl2 expression in macrophages. In vitro, CC10 was found to significantly inhibit the expression of Fgl2 in MHV-3-infected mouse peritoneal macrophages. Such effects may be mediated by the transcription factor HBP1.

  2. The increase in intrahepatic and plasma sFGL2 by Tregs may restrict AIH progression by inhibiting conventional CD8+ T cells and Tc17 cell function. The high correlation between sFGL2 and disease severity may predict AIH outcome.

  3. our results presented herein point to Fgl2 as a novel protective molecule in the pathogenesis of IBD. We found that Fgl2 is critical for limiting DSS-induced colitis and subsequent CAC development through its effects on macrophage polarization

  4. These results indicated that FGL2 might be a promising target for attenuating the severity of Severe acute pancreatitis (SAP) and adenovirus-mediated artificial miRNAs targetting FGL2 represented a potential therapeutic approach for the treatment of SAP.

  5. The results of the present study indicated that, in the colitis model, FGL2 was associated with the immunopathogenesis of inflammatory bowel disease.

  6. FGL2-overexpressing regulatory T-cells have enhanced immunosuppressive activity and prevent colitis; FGL2-over-expressing effector T-cells are hypo-proliferative and do not induce colitis

  7. PD-1 plays a vital role in brain inflammation via regulation of Fgl-2 after ICH, and that manipulation of PD-1 might be a promising therapeutical target in ICH.

  8. In vitro IL-33 treatment abrogated MHV-3 and IFN-gamma induced FGL2 expression in RAW264.7 and THP-1 cells.

  9. FGL2 appears as one of the key players in immune regulatory processes favoring metacestode survival by promoting Regulatory T-cell activity and IL-17A production that contributes to FGL2-regulation.

  10. TNF-alpha, and FGL2 form an integral network that contributes to coagulation and complement activation, and suggest that those are potential therapeutic targets in viral FH intervention.

  11. these data strongly suggest that Treg cells expressing FGL2 mediate rapamycin-induced tolerance. Furthermore, a gene biomarker panel that includes fgl2 can distinguish between rejecting and tolerant grafts.

  12. Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice.

  13. Mouse susceptibility to MHV-3-induced fulminant hepatitis may rely on C5a/C5aR interactions, for which ERK1/2 and p38 pathways participate in up-regulating Fgl2 expression.

  14. Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis.

  15. Cysteines at positions 94, 97, 184 and 187, found in the coiled-coil domain were shown to be crucial for FGL2 oligomerization.

  16. FGL2 binding to the FcgammaRIIB receptor expressed on sinusoidal endothelial cells (SECs) is a critical event in the initiation of the hepatic reperfusion injury cascade through induction of SEC and hepatocyte death.

  17. The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis.

  18. Fgl2 cleaves prothrombin to thrombin consistent with serine protease activity and requires calcium, phospholipids, and factor Va for its full activity.

  19. While membrane-bound Fgl2 acts as a prothrombinase, soluble Fgl2 is an immunomodulatory protein that has the ability to modulate T cell responses and to alter dendritic cell (DC) maturation to favor production of tolerogenic DC.

  20. fgl2 expression in endothelial cells is controlled by Ets-1 and Oct-1, and requires Sp1 and Sp3

Fibrinogen-Like 2 (FGL2) Antigen Profile

Antigen Summary

The protein encoded by this gene is a secreted protein that is similar to the beta- and gamma-chains of fibrinogen. The carboxyl-terminus of the encoded protein consists of the fibrinogen-related domains (FRED). The encoded protein forms a tetrameric complex which is stabilized by interchain disulfide bonds. This protein may play a role in physiologic functions at mucosal sites.

Gene names and symbols associated with Fibrinogen-Like 2 (FGL2) ELISA Kits

  • fibrinogen like 2 (FGL2) antibody
  • fibrinogen like 2 L homeolog (fgl2.L) antibody
  • fibrinogen-like 2a (fgl2a) antibody
  • fibrinogen-like 2 (Fgl2) antibody
  • fibrinogen-like protein 2 (Fgl2) antibody
  • AI385601 antibody
  • FGL2 antibody
  • fibroleukin antibody
  • musfiblp antibody
  • pT49 antibody
  • si:ch211-276e22.3 antibody
  • T49 antibody
  • wu:fj83c10 antibody
  • zgc:136619 antibody

Protein level used designations for Fibrinogen-Like 2 (FGL2) ELISA Kits

fibrinogen-like 2 , fibroleukin , fibroleukin-like , fibrinogen-like protein 2 , associated with MHV-3 induced prothrombinase activity , cytotoxic T-lymphocyte-specific protein , prothrombinase

475902 Canis lupus familiaris
495355 Xenopus laevis
565637 Danio rerio
694856 Macaca mulatta
768821 Gallus gallus
100228349 Taeniopygia guttata
100351573 Oryctolagus cuniculus
100393441 Callithrix jacchus
100439476 Pongo abelii
100608696 Pan troglodytes
100619845 Monodelphis domestica
10875 Homo sapiens
84586 Rattus norvegicus
448808 Sus scrofa
511711 Bos taurus
14190 Mus musculus
Selected quality suppliers for Fibrinogen-Like 2 (FGL2) ELISA Kits
Did you look for something else?